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Merging tumor targeting and molecular-genetic
imaging into an integrated platform is limited by
lack of strategies to enable systemic yet ligand-
directed delivery and imaging of specific trans-
genes. Many eukaryotic viruses serve for trans-
gene delivery but require elimination of native
tropism for mammalian cells; in contrast, pro-
karyotic viruses can be adapted to bind tomam-
malian receptors but are otherwise poor ve-
hicles. Here we introduce a system containing
cis-elements from adeno-associated virus
(AAV) and single-stranded bacteriophage. Our
AAV/phage (AAVP) prototype targets an integ-
rin. We show that AAVP provides superior
tumor transduction over phage and that incor-
poration of inverted terminal repeats is asso-
ciatedwith improved fate of the delivered trans-
gene. Moreover, we show that the temporal
dynamics and spatial heterogeneity of gene ex-
pression mediated by targeted AAVP can be
monitored by positron emission tomography.
This new class of targeted hybrid viral particles
will enable a wide range of applications in biol-
ogy and medicine.
INTRODUCTION
Integration of tumor targeting and imaging technologies
into a single discipline has the potential to improve the
practice of medicine. Noninvasive molecular-genetic im-
aging of temporal dynamics and spatial heterogeneity oftransgene expression can provide the means for the as-
sessment of specificity of targeting and for monitoring
the efficacy of genetic transfer (Blasberg and Tjuvajev,
2003; Gross and Piwnica-Worms, 2005a; Medintz et al.,
2005; Tai and Laforest, 2005). However, this emerging
field depends on development of ligand-directed particles
to enable systemic targeted delivery and molecular imag-
ing of reporter trangenes.
Currently, eukaryotic viruses unquestionably provide
superior transgene delivery and transduction (Kootstra
and Verma, 2003), but ligand-directed targeting of such
vectors requires ablation of their native tropism for mam-
malian cell-membrane receptors (Mu¨ller et al., 2003; Miz-
uguchi and Hayakawa, 2004). In contrast, prokaryotic
viruses such as bacteriophage (phage) are considered
poor vehicles for mammalian cell transduction. However,
despite their inherent shortcomings as ‘‘eukaryotic’’
viruses, phage particles have no tropism for mammalian
cells (Barrow and Soothill, 1997; Barbas et al., 2001) and
have even been adapted to transduce such cells (Ivanen-
kov et al., 1999; Larocca et al., 1999; Poul and Marks,
1999; Piersanti et al., 2004), albeit at low efficiency. Phage
display-based technology allows direct ligand-directed
selection of homing peptides to corresponding receptors
selectively expressed in normal or tumor tissues (Hajitou
et al., 2006). We hypothesized that combining the favor-
able biological attributes of eukaryotic viruses to those
of prokaryotic viruses might yield chimeric particles with
potential as targeted delivery tools for molecular imaging.
Since the genomes of recombinant adeno-associated
virus (AAV) and single-stranded phage consist of compat-
ible DNA, we generated novel chimeras between AAV and
fd-tet (Zacher et al., 1980), an M13-derived filamentous
phage, displaying short peptides (Smith and Scott, 1993)
and evaluated them for tumor targeting and molecular im-
aging of Herpes simplex virus thymidine kinase (HSVtk)Cell 125, 385–398, April 21, 2006 ª2006 Elsevier Inc. 385
gene expression with [18F]FEAU and positron emission
tomography (PET) in preclinical tumor models.
RESULTS AND DISCUSSION
Ligand-Directed Particles Are Functional
in Mammalian Cells
As a proof of concept, we constructed a targeted chimeric
virus comprised of recombinant AAV and an fd-tet phage
clone displaying the double-cyclic peptide CDCRGDCFC
(termed RGD-4C) phage (Pasqualini et al., 1997; Arap
et al., 1998; Ellerby et al., 1999). The RGD-4C peptide
binds to av integrins, a cell-surface receptor overex-
pressed in both tumor and endothelial cells (Arap et al.,
1998; Hood et al., 2002). To obtain chimeric viruses (here-
after referred to as AAV/phage; AAVP), we inserted an
eukaryotic gene cassette from AAV in an intergenomic re-
gion of RGD-4C phage (RGD-4C AAVP); insertless phage
(nontargeted AAVP); or phage displaying control peptides,
such as scrambled RGD-4C AAVP or D/E mutant
(termed RGE-4C) AAVP, and packaged it with the phage
DNA into the phage capsid (see Figure S1 in the Supple-
mental Data available with this article online). In order to
show that the cis-elements of the resulting targeted chi-
meric virus remain functional, we evaluated the ligand
properties of the RGD-4C peptide and the rescuing prop-
erties of the inverted terminal repeats (ITRs) in the context
of AAVP. First, to evaluate peptide specificity, we show
that RGD-4C AAVP binds to mammalian cells expressing
av integrins, in contrast to the nontargeted AAVP or AAVP
displaying negative control peptides such as RGE-4C or
various scrambled versions of the RGD-4C sequence
(Figure 1A), which neither bind to nor infect mammalian
cells. We also demonstrate that RGD-4C AAVP carrying
reporter genes canmediate ligand-directed internalization
(Figure 1B) and transduction of mammalian cells (Fig-
ure 1C) relative to controls. For cell internalization experi-
ments, negative controls included nontargeted AAVP,
various scrambled RGD-4C AAVP, or RGE-4C AAVP (Fig-
ure 1B); for cell transduction experiments, nontargeted
AAVP (Figure 1C), scrambled RGD-4C AAVP, or RGE-4C
AAVP (data not shown) served as negative controls. Con-
sistent with these results, we have previously demon-
strated that the synthetic RGD-4C peptide specifically
inhibits cell binding and internalization of various targeted
RGD-4C phage-based constructs (Giordano et al., 2001;
Chen et al., 2004; unpublished data). Finally, we show
that mammalian cell transduction can also be specifically
competed by the synthetic RGD-4C peptide relative to
negative controls such as nontargeted AAVP (Figure 1D),
scrambled RGD-4C, or RGE-4C (data not shown). To
rule out the possibility that some of these results (Figures
1A and 1B) could represent an artifact resulting from se-
lective failure of the glycine (low pH) wash step to remove
AAVP from cell membranes, we performed ice-cold con-
trol experiments (Giordano et al., 2001), in which we
observed cell binding but not internalization mediated by386 Cell 125, 385–398, April 21, 2006 ª2006 Elsevier Inc.RGD-4C AAVP (data not shown), thus supporting our
interpretation.
Next, to evaluate whether the ITRs are still functional in
the AAVP particle, we performed rescue experiments. We
show that functional recombinant AAV particles are gener-
ated from mammalian cells transduced with the RGD-4C
AAVP only but not from the cells transduced with negative
control constructs (Figure 1E). These data establish that
the genetic chimerization resulting in an RGD-4C AAVP
particle does not fundamentally alter (1) the peptide tar-
geting properties of the ligand-directed RGD-4C phage
or (2) the ability to rescue recombinant AAV particles
from mammalian cells transduced by RGD-4C AAVP. A
side-by-side time course of a reporter transgene expres-
sion revealed that RGD-4C AAVP transduction was
detectable for much longer compared to that of the
RGD-4C phage (Table S1).
Molecular Mechanisms of Transgene Expression
To gain an insight into themolecular mechanisms of trans-
gene expression mediated by AAVP, we investigated the
fate of the transduced genome in mammalian cells. First,
we generated stably transduced cell lines by using
GFPneo-expressing AAVP to allow for the selection of
individual transduced cell clones. Either RGD-4C AAVP-
GFPneo or RGD-4C phage-GFPneo lacking AAV ITRs
were used to transduce av integrin-expressing 293 cells,
and clones were isolated under G418 selection. Rescue
experiments showed functional recombinant AAV-
GFPneo generated from all of the RGD-4C AAVP-GFPneo
293 cell clones, but none generated from the RGD-4C
phage-GFPneo clones (data not shown), thus confirming
that the chimeric individual clones contain functional
ITRs. Although cells transduced with the nonchimeric
RGD-4C phage-GFPneo retained G418 resistance, GFP
expression was generally weaker than that of the RGD-
4C AAVP-GFPneo clones (Figure 2A). We then set out to
determine the fate of the GFPneo transgene cassette in
stably transduced clones by a comprehensive restric-
tion-enzyme digestion of genomic DNA followed by
Southern blotting and PCR analysis (Figure 2; Figure S2
and Table S2). To prove persistence of the transgene cas-
sette, genomic DNA was digested with AflII and XhoI to
detect the release of full-length transgene cassettes prior
to the analysis. We observed such release in 100% of the
clones transduced by RGD-4C AAVP (n = 9 of 9 clones),
compared to only in 33% of the clones (n = 3 of 9 clones)
transduced by the nonchimeric RGD-4C phage construct
(Figure 2B). We next designed another restriction digest of
genomic DNA to detect potential concatemeric forms of
the transgene cassette (Lieber et al., 1999; Hsiao et al.,
2001). We detected the presence of head-to-tail conca-
temers of the transgene cassette in 67% of the clones
transduced by RGD-4C AAVP (n = 6 of 9 clones), while
no such concatemers were detected in clones transduced
by the nonchimeric RGD-4C phage construct (Figure 2C).
To identify possible additional concatemeric forms of the
transgene cassette, we performed a multiplex PCR by
Figure 1. Ligand-Directed RGD-4C AAVP Transduction of av Integrin-Expressing Cells and Rescue of Recombinant AAV
(A and B) Phage binding and internalization in KS1767 cells were performed with RGD-4C AAVP or negative AAVP controls (nontargeted, scrambled,
or mutated) as indicated.
(C) Targeted gene transfer mediated by RGD-4C AAVP-b-gal to KS1767 cells.
(D) Inhibition of transduction by the synthetic RGD-4C peptide but not by an unrelated control peptide; nonspecific transduction levels were deter-
mined by using nontargeted AAVP. An anti-b-gal antibody was used for staining, and gene expression was detected by immunofluorescence. Error
bars indicate standard error of the mean (SEM) obtained from duplicate wells.
(E) Rescue of recombinant AAV from cells infected with RGD-4C AAVP. Human 293 cells were incubated with targeted RGD-4C AAVP-GFP (106 TU/
cell) or negative controls (targeted nonchimera RGD-4C phage-GFP, nontargeted AAVP-GFP). Four days postinfection, cells were transfectedwith an
AAV rep- and cap-expressing plasmid (pXX2; Xiao et al., 1998) and superinfected with wild-type adenovirus type 5 (Ad). Cells were harvested 72 hr
post adenoviral infection, and supernatants were then used to infect new 293 cells. GFP expression was FACS analyzed 48 hr later. Shown are mean
increases in recombinant AAV-GFP produced over background after rescue from each construct. Data presented are the mean of triplicate trans-
fections, and error bars represent the standard deviation (SD) from the mean.using primers flanking the 50 and 30 ends of the constructs.
Again, we found no concatemers in clones transduced by
nonchimeric RGD-4C phage construct, whereas 100% of
clones transduced by RGD-4C AAVP contained concate-
meric forms (n = 9 of 9 clones), all of them found in head-
to-tail orientation (Figure S2B). Moreover, topo cloning of
smaller PCR products revealed the head-to-tail orienta-
tion of the transgene cassette with ITR deletions (Fig-
ure S2C) (Yang et al., 1997). Finally, although the large
PCR products could not be sequenced, their sizes sug-
gest the presence of concatemers with intact ITRs atthe junction site. An individual analysis of DNA for each
single clone is also detailed in Table S2. These data sug-
gest that AAVPmay bestow an advantage in gene expres-
sion by means of an altered fate of the transgene cassette
through maintenance of the entire mammalian transgene
cassette, better persistence of episomal DNA, formation
of concatemers of the transgene cassette, or perhaps
a combination of these non-mutually exclusive mecha-
nisms. These observations are consistent with recent de-
velopments in the understanding of AAV (McCarty et al.,
2004).Cell 125, 385–398, April 21, 2006 ª2006 Elsevier Inc. 387
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Tumor Targeting In Vivo and
Molecular-Genetic Imaging
After demonstrating that the central elements of the tar-
geted chimeric viral particle (i.e., the RGD-4C peptide
and the AAV ITRs) are intact and functional and after elu-
cidating the molecular mechanisms of AAVP-mediate
gene expression in mammalian cells, we evaluated the
specificity and efficacy of gene delivery into tumors after
systemic administration of AAVP. As an initial preclinical
model, we used nude mice bearing subcutaneous tumor
xenografts derived from human Kaposi sarcoma KS1767
cells (Arap et al., 1998; Ellerby et al., 1999). First, to verify
that the viral construct targets to KS1767-derived xeno-
grafts in mice, we intravenously administered either
RGD-4C AAVP or one of several negative controls (nontar-
geted AAVP, scrambled RGD-4C AAVP, or RGE-4C
AAVP). After a 3–5 min circulation time, a strong anti-
AAVP staining in tumor vasculature was observed in
mice that received RGD-4C AAVP but not in control
mice (Figure 3A). We next used an RGD-4C AAVP variant
encoding the GFP gene as a reporter to determine, by us-
ing in situ immunofluorescence microscopic imaging,
whether this vector (RGD-4C AAVP-GFP) could transduce
KS1767-derived xenografts. We performed immunostain-
ing against GFP in tumors and in different organs 7 days
after systemic administration of either RGD-4C AAVP-
GFP or negative control constructs into tumor-bearing
mice. Immunofluorescence revealed GFP expression
largely in tumor blood vessels and surrounding tumor cells
in mice that received RGD-4C AAVP-GFP. In contrast, no
GFP staining was detected in tumors from control mice
that received nontargeted, scrambled, or mutant AAVP-
GFP (Figure 3B). This staining pattern suggests that li-
gand-directed transduction is mediated by targeting of
av integrins in the vascular endothelium of tumors. Con-
sistently, several nontarget control organs (brain, liver,
pancreas, and kidney) lacked tissue expression of GFP
(Figure S3). These results indicate that RGD-4CAAVP par-
ticles can specifically target tumor xenografts by a ligand-
directed mechanism and transduce them after systemic
administration in vivo.
Next, we assessed the efficacy of preclinical biolumi-
nescence imaging (BLI) and clinically applicable molecu-
lar-genetic PET imaging with [18F]FEAU for noninvasive
monitoring of temporal dynamics and spatial heterogene-
ity of the firefly luciferase (Luc) and the HSVtk reporter-
gene expression, respectively, in living tumor-bearing
mice following systemic administration of the RGD-4CAAVP. These molecular-genetic imaging studies were
conducted in a preclinical model of human prostate can-
cer since this particularly prevalent tumor remains a chal-
lenge to properly image in patients. We first used a stan-
dard experimental setup for in vivo imaging of the Luc
transgene reporters in tumor-bearing mice (Figure 4A).
We selected BLI of Luc expression because it is a very
sensitive method for reporter-gene imaging in mice and
has virtually no nonspecific background activity in the
images (Gross and Piwnica-Worms, 2005a; Gelovani Tju-
vajev and Blasberg, 2003). Tumor-specific expression of
Luc was observed in DU145 tumors in mice receiving
RGD-4C AAVP-Luc. In contrast, tumor-associated biolu-
minescence signals could not be observed in control
mice receiving the nontargeted AAVP-Luc or scrambled
RGD-4C AAVP-Luc. No bioluminescence was observed
in normal organs with any AAVP tested. These data
confirm the tumor specificity of RGD-4C AAVP-mediated
targeting and transgene expression observed with immu-
nofluorescencemicroscopy imaging studieswith RGD-4C
AAVP-GFP. Consistent with previous results presented
here (Figure S3), the kinetics of distribution suggests
that, despite the nonspecific hepatic clearance of phage
particles (Geier et al., 1973), such a phenomenon does
not result in an undesirable gene transduction of the liver.
These observations are in sharp contrast with the well-
documented nonspecific transduction of normal organs
(such as liver) by the mammalian viral gene delivery vec-
tors. By using BLI in vivo, Luc reporter-transgene expres-
sion within tumors was clearly detectable at day 3 after
AAVP administration and increased gradually to reach
maximal levels by day 10. Repetitive two-dimensional
BLI of Luc reporter-gene expression was performed every
other day and provided an initial cost-effective strategy to
study the specificity, temporal dynamics, and spatial het-
erogeneity of reporter-transgene expression mediated by
AAVP.
However, because BLI of Luc reporter-gene expression
is not clinically applicable, we next introduced into the
AAVP vector the HSVtk gene, which can serve as both
a ‘‘suicide’’ gene (when combined with ganciclovir
[GCV]) and a reporter transgene for clinically applicable
PET imaging with HSVtk-specific radiolabeled nucleoside
analogs ([124I]FAIU, [18F]FHBG, [18F]FEAU). Previous stud-
ies established that PET imaging of HSVtk expression
provides the ability to define the location, magnitude,
and duration of transgene expression (Tjuvajev et al.,
1998, 1999; Ray et al., 2001; Massoud and Gambhir,Figure 2. Analysis of the Fate of Genomes from RGD-4C AAVP-GFPneo or from RGD-4C Phage-GFPneo upon Transduction
We generated 293 stable clonal cell lines (n = 9 per each group) that were then analyzed. Individual clones were termed AAVP 1–9 or phage 1–9.
Nontransduced 293 parental cells served as a negative control.
(A) Histogram shows a summary of flow cytometric analyses of 293 clones stably transduced with either AAVP-GFPneo (n = 9) or phage-GFPneo
(n = 9). Open triangles indicate percentages of GFP-positive cells; black bars represent GFP expression levels (mean fluorescent intensity; MFI).
(B) Southern blot analysis of the persistence of the transgene cassette in clonal cell lines transduced with RGD-4C AAVP-GFPneo or RGD-4C phage-
GFPneo. Total cellular DNA from nontransduced 293 parental cells or each of the transduced cell clones (1–9 for each group) was double digested
with AflII-XhoI (one restriction site per enzyme within the construct DNA flanking the transgene cassette).
(C) Analysis of potential head-to-tail concatemers of the transgene cassette by Southern blot. Total cellular DNA was digested with XhoI (single
restriction site within the transgene cassette next to the 30 ITR) prior to Southern blotting.Cell 125, 385–398, April 21, 2006 ª2006 Elsevier Inc. 389
Figure 3. RGD-4C AAVP-Mediated Spe-
cific Gene Delivery to Tumors
(A) Immunohistochemical staining against
phage in KS1767-derived xenografts after in-
travenous administration of RGD-4C AAVP
(5 1010 TU) or negative controls (nontargeted
AAVP, scrambled RGD-4C AAVP, or RGE-4C
AAVP) into nude mice bearing KS1767-derived
tumor xenografts. AAVP constructs were al-
lowed to circulate for 5 min, followed by perfu-
sion and surgical removal of tumors. Arrows
point to phage staining in tumor blood vessels.
(B) Immunofluorescence analysis of GFP ex-
pression in KS1767-derived xenografts at day
7 after systemic administration of either RGD-
4C AAVP-GFP or negative controls (nontar-
geted, scrambled, or mutant) as indicated.2003). It has also been previously determined that the
magnitude of accumulated radiolabeled tracers in HSVtk-
transduced cell lines and tumors in vivo correlates with the
level of HSVtk expression (Blasberg and Tjuvajev, 2003;
Gross and Piwnica-Worms, 2005a; Tai and Laforest,
2005). In the studies presented here, we selected, synthe-
sized, and used the radiolabeled nucleoside analog
20-[18F]-fluoro-20-deoxy-1-b-D-arabino-furanosyl-5-ethyl-
uracil ([18F]FEAU), which is a better radiolabeled substrate
for the HSVtk enzyme than other nucleoside analogs, es-
pecially from pharmacokinetic considerations (a very low
background activity in all normal organs and tissues)
(Kang et al., 2005). By using repetitive PET imaging with
[18F]FEAU (on days 0, 3, 5, 10, and 16), we have visualized
and quantitated the temporal dynamics and spatial het-
erogeneity of HSVtk gene expression after a single sys-
temic administration of RGD-4C AAVP-HSVtk or nontar-
geted AAVP-HSVtk in DU145-derived tumor xenografts
and other organs and tissues in nudemice (Figure 4B). Tu-390 Cell 125, 385–398, April 21, 2006 ª2006 Elsevier Inc.mor xenograft sizes (150 mm3) before, as well as tumor
growth rates after, administration of either RGD4C AAVP-
HSVtk or nontargeted AAVP-HSVtk were similar in both
cohorts of mice (Figure 4C). PET imaging with [18F]FEAU
revealed a gradual increase in the level ofHSVtk transgene
expression in tumors (increase in % administered intrave-
nous dose per gram) during the initial 5 days after admin-
istration of RGD-4C AAVP-HSVtk, followed by gradual
stabilization of HSVtk expression levels toward day 10
post vector administration. In contrast, in control tumor-
bearing mice receiving nontargeted AAVP-HSVtk, only
a minor increase in tumor accumulation of [18F]FEAU
was observed at day 3, which rapidly decreased to back-
ground level (Figure 4D). Consistent with preceding BLI
experiments, no [18F]FEAU PET-detectable HSVtk ex-
pression was observed in nontarget organs or tissues
(Figure 4B). Indeed, low-level heterogeneous activity in
the PET images (blue color) represents normal back-
ground activity, which was intentionally intensified in the
Figure 4. Targeted AAVP-Mediated Molecular Imaging of Tumor-Bearing Mice
(A) In vivo bioluminescent imaging (BLI) of luciferase expression after systemic AAVP delivery. Nude mice bearing DU145-derived tumor xenografts
received an intravenous single dose of either RGD-4C AAVP-Luc (5 1011 TU) or controls (nontargeted AAVP-Luc or scrambled RGD-4C AAVP-Luc).
Ten days later, BLI of tumor-bearing mice was performed.
(B) Multitracer PET imaging in tumor-bearing mice after systemic delivery of RGD-4C AAVP-HSVtk. Nude mice bearing DU145-derived tumor xeno-
grafts (n = 9 tumor-bearing mice per cohort) received an intravenous single dose (5 1011 TU) of RGD-4C AAVP-HSVtk or nontargeted AAVP-HSVtk.
PET images with [18F]FDG and [18F]FEAU obtained before and after GCV treatment are presented. T, tumor; H, heart; BR, brain; BL, bladder. Cali-
bration scales are provided in (A) and (B). Superimposition of PET on photographic images of representative tumor-bearing mice was performed to
simplify the interpretation of [18F]FDG and [18F]FEAU biodistribution.
(C) Growth curves of individual tumor xenografts after AAVP administration.
(D) Temporal dynamics of HSVtk gene expression as assessed by repetitive PET imaging with [18F]FEAU at different days post AAVP administration.
(E) Changes in tumor viability before and after GCV therapy as assessed with [18F]FDG PET. Error bars in (C)–(E) represent standard deviations (SD).Cell 125, 385–398, April 21, 2006 ª2006 Elsevier Inc. 391
Figure 5. Tumor Growth Suppression by RGD-4C AAVP-HSVtk Transduction plus Ganciclovir
(A–C) Cohorts of immunodeficient nude mice with established human xenografts (50 mm3) derived from KS1767 cells (A), bladder UC3 carcinoma
cells (B), or prostate DU145 carcinoma cells (C) received a single intravenous administration (5 1010 TU) of RGD-4C AAVP-HSVtk or controls (non-
targeted AAVP-HSVtk, RGD-4C AAVP-GFP, or vehicle alone). GCV was administered to mice from posttreatment day 2 until the end of the exper-
iments. All mice received GCV except for a control group treated with RGD-4C AAVP-HSVtk and no GCV afterwards. Shown are the mean tumor
volumes ± standard deviations (SD).
(D) Growth inhibition of large DU145-derived xenografts (at 150 mm3) by a single intravenous dose (5  1010 TU) of RGD-4C AAVP-HSVtk.
(E) Inhibition of tumor growth of EF43-FGF4mousemammary carcinoma (50mm3) in immunocompetent BALB/c mice by a single intravenous dose
(5  1010 TU) of RGD-4C AAVP-HSVtk.392 Cell 125, 385–398, April 21, 2006 ª2006 Elsevier Inc.
images presented to demonstrate that no truncation of
low levels of radioactivity was made to artificially ‘‘im-
prove’’ the specificity of HSVtk expression in tumors
versus nontarget tissues. When tumors grew to reliably
palpable sizes (350–400 mm3) and a plateau of HSVtk
expression was achieved in tumors, treatment with GCV
was initiated in all cohorts of animals (Figure 4C). PET im-
aging with [18F]fluorodeoxyglucose ([18F]FDG) served to
monitor glucose metabolism and GCV-induced changes
in tumor viability. Two days before initiation of GCV ther-
apy (day 9 post vector administration), the DU145 tumors
in both groups of mice were viable and actively accumu-
lated [18F]FDG (Figure 4E). After GCV therapy, the volume
of tumors in mice that received RGD-4C AAVP-HSVtkwas
significantly smaller than in mice that received nontar-
geted AAVP-HSVtk (p < 0.05; Figure 4C). Moreover, tumor
xenografts were also metabolically suppressed, as evi-
denced by a decrease in accumulation of [18F]FDG (Fig-
ure 4E). The levels of HSVtk expression in tumors of
mice administered with RGD-4C AAVP-HSVtk were also
significantly decreased after GCV therapy, as evidenced
by a sharp decrease in [18F]FEAU accumulation in PET im-
ages (Figure 4D), which were obtained 24 hr after the last
GCV dose (to avoid competition with FEAU). These stud-
ies confirm the specificity of tumor targeting by RGD-4C
AAVP and demonstrate that the level of HSVtk transgene
expression is adequately high for effective prodrug activa-
tion of GCV.
In order to evaluate efficacy horizontally in other preclin-
ical models, we assembled a panel of tumor cell lines from
different species and histological origins and generated
tumors in immunosuppressed or immunocompetent
mice. Cohorts of Kaposi sarcoma (KS1767) derived tu-
mor-bearing mice systemically received a single intra-
venous dose of either the RGD-4C AAVP-HSVtk or nontar-
geted AAVP-HSVtk (control), followed by GCV treatment
in all groups. Marked tumor growth suppression was ob-
served in tumor-bearing mice receiving RGD-4C AAVP-
HSVtk as compared to mice treated with vehicle or mice
that received nontargeted AAVP (Figure 5A). Similar tumor
growth-suppressive effects were observed in UC3-de-
rived bladder carcinomas (Figure 5B) and DU145-derived
prostate carcinomas (Figure 5C) in nude mice, even if
larger tumor xenografts were treated (Figure 5D) and con-
sistent with the imaging results presented (Figure 4).
To rule out the possibility that the observed antitumor
effects were either species specific or xenograft specific,
we sought to analyze the efficacy of the RGD-4C AAVP-
HSVtk on a standard mouse tumor model. We chose anisogenic tumor in which EF43-FGF4 mouse mammary
cells are administered subcutaneously to induce rapid
growth of highly vascularized tumors in immunocompe-
tent mice (Hajitou et al., 2001). First, we established the
ligand-directed homing of RGD-4C AAVP to EF43-FGF4-
derived tumors by anti-phage immunostaining (Figure S4).
Either RGD-4C AAVP-GFP or nontargeted AAVP-GFP
was administered intravenously to mice bearing isogenic
mammary tumors for a 3–5 min circulation time. Unlike
the nontargeted AAVP-GFP, RGD-4C AAVP-GFP pro-
duced a strong anti-phage staining in tumors (Figure S4A).
Next, we performed immunofluorescence with an anti-
GFP antibody at 7 days after intravenous administration
to reveal strong GFP expression in the tumors in mice
that received RGD-4C AAVP-GFP; in contrast, no GFP
staining was detected in tumors from mice that received
nontargeted AAVP-GFP; consistently, an anti-av integrin
antibody detected strong expression in EF43-FGF4
tumors (Figure S4B). Again, a single systemic dose of
RGD-4C AAVP-HSVtk followed by GCV markedly in-
hibited the growth of EF43-FGF-4 tumors (Figures 5E–
5G and Figure 6). Moreover, when tumors grew back after
termination of therapy, repeated administrations of RGD-
4C AAVP-HSVtk again inhibited EF43-FGF4 tumor growth
and improved survival of tumor-bearing mice (Figure 5F).
Phage-based particles are known to be immunogenic,
but this feature can be modulated through targeting itself
(Trepel et al., 2001). In fact, RGD-4C AAVP-HSVtk plus
GCV remained surprisingly effective on phage-vaccinated
immunocompetent mice despite very high titers of circu-
lating anti-phage IgG (Figure 5G). In selective experi-
ments, a comprehensive panel of negative experimental
controls including vehicle alone, vehicle plus GCV, nontar-
geted AAVP, nontargeted AAVP plus GCV, targeted RGD-
4C AAVP, targeted RGD-4C AAVP-GFP, and targeted
RGD-4C AAVP-GFP plus GCV (mock transduction) were
used (Figure 6A and data not shown).
To check for posttreatment effects, we obtained de-
tailed histopathological analysis of EF43-FGF4 tumors re-
covered 7 days after therapy. We noted extensive tumor
destruction caused by the single systemic dose of RGD-
4C AAVP-HSVtk plus GCV. Specifically, hematoxylin and
eosin (H&E) staining revealed uniform destruction of the
central area of the tumor and only a small viable outer
rim; in contrast, nontargeted AAVP-HSVtk had no such
effect (Figure 6B). Staining with an anti-CD31 antibody
confirmed both disrupted tumor blood vessels within the
tumor central region and preserved vasculature toward
the outer rim, whereas no damage was observed in the(F) Long-term efficiency of RGD-4C AAVP-HSVtk and GCV by repeated intravenous doses of AAVP (5  1010 TU per dose) to immunocompetent
BALB/c mice bearing isogenic EF43-FGF4 tumors. Therapy results were consistently observed in independent experiments with tumor-bearing
mice cohorts (n = 10 mice per treatment group). Arrows indicate times of AAVP administration.
(G) Effect of humoral immune response against phage on therapy with RGD-4C AAVP-HSVtk. BALB/c immunocompetent mice (n = 7mice per group)
were first ‘‘vaccinated’’ with RGD-4C AAVP-GFP (1010 TU per week for 3 weeks, intravenous) and then implanted with EF43-FGF4 cells. Tumor-bear-
ing mice received a single systemic dose of RGD-4C AAVP-HSVtk or nontargeted AAVP-HSVtk followed by GCV maintenance (started at day 2 post
AAVP administration). Vaccination did not affect the antitumor effects, despite high anti-phage antibody titers (up to 1:10,000). Error bars in (D)–(G)
represent standard deviations (SD).Cell 125, 385–398, April 21, 2006 ª2006 Elsevier Inc. 393
Figure 6. Histological Analysis of Representative Experiments
(A) Tumor-bearing mice (upper panel) and corresponding surgically removed tumors (lower panel) from all the experimental groups of therapy (EF43-
FGF4 mammary tumors in BALB/c immunocompetent mice).
(B) Histopathologic analysis of EF43-FGF4 treated tumors. Nontargeted AAVP-HSVtk-treated tumors (left panels), the border between the outer rims
and central tumor areas (middle panels), and central tumor areas of RGD-4C AAVP-HSVtk-treated tumors (right panels) are shown as high-magni-
fication views from the low-magnification inserts of serial tumor sections. Hematoxylin and eosin (H&E) staining, CD31 immunostaining (arrows, tumor
blood vessels), and TUNEL staining (arrows, apoptotic cells) are shown.tumors treated with nontargeted AAVP-HSVtk (Figure 6B).
We also evaluated the tumors for terminal deoxynucleo-
tidyl-transferase-mediated dUTP-biotin nick end labeling394 Cell 125, 385–398, April 21, 2006 ª2006 Elsevier Inc.(TUNEL) staining, which marks apoptotic cells, because
the HSVtk/GCV strategy is associated with apoptotic
deathof cells. In tumors treatedwithRGD-4CAAVP-HSVtk
andGCV, TUNEL staining detected apoptosis in the tumor
central region but not within the outer rim, while no apo-
ptosis was observed in tumors from mice that received
nontargeted AAVP-HSVtk chimera (Figure 6B). Control
organs removed from tumor-bearing mice treated by the
same experimental protocol revealed no histopathologic
abnormalities (Figure S5). Together, these results show
that a single systemic dose of RGD-4C AAVP-HSVtk
plus GCV maintenance can suppress tumor growth.
Some of our results merit further discussion. First, the
relative contribution of targeting each tumor compartment
(i.e., tumor cells versus tumor vascular endothelium and/
or stroma) will depend on the ligand-receptor system
and on the experimental model (or models) used. For
instance, the expression of the membrane target (i.e., av
integrins) in tumor cells will vary from low (EF43-FGF4)
to strong (KS1767). Moreover, aside from the specific op-
timal dose for transduction of each model (and applica-
tion) used, there is also an optimal time to examine trans-
gene expression. In other words, the stoichiometry of
reporter-gene expression depends not only on levels
and patterns of reporter expression in individual cells but
also on the relative number of proliferating transgene-
expressing cells versus dying transgene-expressing cells.
Thus, while we used fixed parameters for the experiments
presented here, further determination of targeted AAVP
optimal doses and timeframes on a case-by-case basis
still apply. Future translational studies will need to be con-
ducted to determine what doses are clinically meaningful
and how an AAVP-based system can be optimized for
therapy of patients by using clinically applicable molecu-
lar-genetic imaging with PET.
Finally, one might speculate that a broad range of cur-
rently intractable biological questions well beyond molec-
ular oncology will be addressed by using targeted AAVP,
especially in combination with different preclinical and
clinical molecular-genetic imaging settings. For example,
the systemic ligand-directed delivery of constructs with
tissue- and/or disease-specific promoters (instead of a
CMV promoter) to target sites will allow monitoring ex-
pression of their corresponding native genes in vivo;
such promoter-driven transcription of reporter activity
will allow the study of cell trafficking and engraftment.
Several noninvasive imaging applications such as experi-
mental monitoring of substrate-specific degradation, pro-
tein-protein interactions, and other molecular events via
reporter transactivation, complementation, or reconstitu-
tion strategies in cells and in whole animals (Luker et al.,
2004; De and Gambhir, 2005; Gross and Piwnica-Worms
2005b) will likely follow. In fact, we have recently de-
scribed networks of gold nanoparticles and bacterio-
phage as biological sensors and cell targeting agents
(Souza et al., 2006); such technology can be combined
with ligand-directed AAVP to further improve molecular-
genetic imaging. On another note, AAVP itself may provide
suitable reagents to study the mechanistic role of ITR
structures in transgene persistence and chromosomal in-
tegration since (in contrast to AAV vectors) phage-basedconstructs with no ITRs can serve as negative experimen-
tal controls. In translational terms, the results presented
here bode well with an existing framework leading to di-
rect AAVP-based random peptide library screening in pa-
tients (Arap et al., 2002; Pentz et al., 2005) and may form
the basis for the discovery of new or unrecognized human
ligand receptors. Thus,many other systemic targeting and
imaging applications in tandem will become possible in
a relatively short time frame.
Conclusions
Ligand-directed AAVP combines desirable properties
from two unrelated genetic systems to yield a targeted
particle for molecular imaging. Attractive features include
a cheap and high yield of production in host bacteria and
no requirements for helper viruses or trans-acting factors.
Moreover, the native tropism of AAV for mammalian cells
is eliminated since there is no AAV capsid formation and
the displayed ligand peptides allow homing to tissue-
specific receptors. In the prototype presented here, the li-
gand-directed AAVP sustains no loss of systemic phage
targeting properties and even acquires some posttarget-
ing patterns associatedwith AAV.We have previously pro-
posed thatmolecular imaging ofmarker geneswould have
the potential to assess therapeutic levels of expression
and markedly improve our ability to predict response to
therapies in which target genes are known. The introduc-
tion of ligand-directed AAVP for systemic targeting and
molecular-genetic imaging, rationally designed along the
lines described here, is a major step in that direction. Fi-
nally, one might speculate that (1) in addition to ligand-
directed targeting, further platform refinements such as
transcriptional targeting will certainly be possible by incor-
poration of specific promoters and (2) other hybrid viruses
containing prokaryotic and eukaryotic elements (such as,
for instance, chimeras between adenovirus and double-
stranded lambda phage) may also be envisioned for sys-
temically targeted imaging of reporters. Based on this
comprehensive analysis, it seems that the translation of
our prototype particle may lead to realistic imaging of
gene expression in cancer patients. In a larger context,
given the favorable tissue-targeting and molecular-imag-
ing profiles, ligand-directed AAVP is likely to be a useful
tool in dissecting other relevant biological questions.
EXPERIMENTAL PROCEDURES
Design, Construction, and Generation of Targeted
AAVP Particles
RGD-4C phage and RGD-4CAAVPwere engineered in a two-step pro-
cess: generation of an intermediate (RGD-4C fUSE5-MCS) and subse-
quent production of RGD-4C phage construct and RGD-4C AAVP.
RGD-4C fUSE5-MCS contained the oligonucleotide insert encoding
the specific targeting peptide RGD-4C and a fragment of the fMCS
plasmid that had a multicloning site (MCS) for insertion of the eukary-
otic expression cassette. RGD-4C phage-derived fUSE5 DNA and
phage-derived fMCS DNA were purified from lysates of E. coli
(MC1061). We obtained the intermediate RGD-4C fUSE5-MCS by li-
gating a 5.4 kb BamHI/SacII fragment of the RGD-4C FUSE5 plasmid
to the 4.1 kb BamHI/SacII fragment of the fMCS plasmid. Next, weCell 125, 385–398, April 21, 2006 ª2006 Elsevier Inc. 395
created a targeted AAVP-GFP by cloning the PacI fragment (2.8 kb) of
pAAV-eGFP plasmid (enhanced GFP; Stratagene) from ITR to ITR into
the PstI site of RGD-4C fUSE5-MSC. Briefly, pAAV was digested with
PacI to release a 2.8 kb fragment, which was blunted with DNA poly-
merase and cloned into the blunted PstI site of RGD-4C fUSE5-
MSC. To generate the targeted phage constructs without ITRs, a
2.3 kb fragment located between the ITRs of pAAV-eGFP and contain-
ing pCMV-GFP and SV40 poly A was released by EcoRI digestion,
blunted, and cloned into the MCS of RGD-4C fUSE5-MSC. To select
cells expressing GFP, the BamHI-SacI fragment of the pQBI phospho-
glycerate kinase-1 (QBIOgene) promoter containing a GFPneo fusion
sequence was cloned in the NotI site of AAVP or control phage con-
structs to ensure that cells expressing GFP were G418- resistant.
The GFPneo fragment of pQBI PGK was released by BamHI and
SacI digestion and blunted with DNA polymerase; then, phosphory-
lated linkers to NotI were added. After NotI digestion, the 1.57 kb
GFPneo fragment was cloned into the NotI site of AAVP or nonchimeric
phage construct. Finally, to generate a targeted AAVP particle carrying
the gene for HSVtk or Luc, the BamHI-NotI fragment containing HSVtk
or Luc was subcloned into the BamHI-NotI site of pAAV plasmid to
replace GFP. The ITR-HSVtk-ITR or ITR-Luc-ITR fragments were re-
moved from pAAV-HSVtk and pAAV-Luc was then inserted into
RGD-4C fUSE5-MCS. Constructs were verified by DNA sequencing
and restriction analysis, purified from the culture supernatant of host
E. coli (MC1061), resuspended in PBS, and recentrifuged. Resulting
supernatants were titrated in E. coli (k91Kan). Serial dilutions were
plated on Luria-Bertani (LB) agar plates containing tetracycline and
kanamycin, and transducing units (TU) were determined by colony
counting.
Mammalian Cell-Surface Binding and Internalization Assays
We used the biopanning and rapid analysis of selective interactive li-
gands (termed BRASIL) method (Giordano et al., 2001) to evaluate
phage binding to intact cells. In brief, KS1767 cells were detached
by EDTA and resuspended in Dulbecco’s modified Eagle’s medium
(DMEM) containing 1% BSA at 4  106 cells/ml. The cell suspension
(50 ml) was incubated with 109 TU of either RGD-4C AAVP or AAVP
clones displaying scrambled versions of RGD-4C (CDCFGDCRC,
CDCGFDCRC, CRCDGFCDC), mutant RGE-4C peptide, or nontar-
geted control. After 2 hr, the AAVP/cell mixture (aqueous phase) was
transferred to the top of a nonmiscible organic phase (200 ml solution
in a 400 ml Eppendorf tube) consisting of dibutyl phthalate:cyclohexane
(9:1 [v/v], D = 1.03 g/ml) and centrifuged at 10,000 g for 10min at 4ºC.
The tube was snap frozen in liquid nitrogen, the bottom of the tube was
sliced off, the pellet was isolated, and membrane bound AAVP was re-
covered.
For cell internalization, KS1767 cells were grown in tissue chamber
slides, washed with PBS, incubated with 109 TU of RGD-4C AAVP or
control AAVP displaying scrambled versions of RGD-4C or RGE-4C
in DMEMcontaining 1%BSA at 37ºC, and washedwith PBS to remove
unbound AAVP after 4 hr incubation. Cell membrane bound clones
were eluted by 20 mM glycine. Next, cells were washed three times
with PBS, fixed with PBS containing 4% PFA at RT for 15 min, washed
with PBS, permeabilized with 0.2% Triton X-100, washed with PBS,
and blocked with PBS containing 1% BSA. Cells were then incubated
with a 1:200 dilution of the primary anti-M13 phage antibody (Amer-
sham) in PBS containing 1% BSA at RT for 2 hr, washed with PBS,
and incubated with a 1:200 dilution of a Cy3-conjugated anti-rabbit
secondary antibody in PBS containing 1% BSA for 1 hr at RT. Finally,
cells were washed with PBS, fixed with PBS containing 4% PFA,
mounted, and visualized in an optical fluorescence microscope.
Recombinant AAV Rescue Assay
Human 293 cells were infected with AAVP or phage. Four days after
infection, cells were transfected with pXX2, an AAV rep- and cap-
expressing plasmid (Xiao et al., 1998), and superinfected with adeno-
virus type 5. Cells were harvested 72 hr post adenoviral infection, and396 Cell 125, 385–398, April 21, 2006 ª2006 Elsevier Inc.supernatants were used to infect new 293 cells. GFP expression was
FACS analyzed 48 hr later.
Generation of Clonal Cell Lines
Human 293 cells were infected with RGD-4C AAVP-GFPneo or RGD-
4C phage-GFPneo (at 106 TUper cell in each case). Single clones (n = 9
per group) were isolated under G418 selection and FACS analyzed for
GFP expression at 12 weeks after selection. Stable clones were
termed phage clones #1–9 for phage-GFPneo and AAVP clones
#1–9 for AAVP-GFPneo.
Tumor Models
Tumor-bearing mice were established and tumor volumes were calcu-
lated as described (Hajitou et al., 2001; Arap et al., 2004; Marchio` et al.,
2004). Mice were anesthetized by intraperitoneal administration of
Avertin or by gas (2% isoflurane and 98% oxygen) inhalation. Tumor
cells were trypsinized, counted, centrifuged, and resuspended in
serum-free medium. A total of 106 cells from Kaposi sarcoma
(KS1767), bladder carcinoma (UC3), or prostate carcinoma (DU145)
lines were implanted subcutaneously into 6-week-old immunodefi-
cient nude mice. The EF43-FGF4 mouse mammary tumor cells (5 
104) were implanted subcutaneously into 6-week-old female BALB/c
immunocompetent mice. When tumors reached a volume of
50mm3 (deemed small) or150mm3 (deemed large) DU145-derived
xenografts (day 0), tumor-bearing mice received a single intravenous
dose of RGD-4C AAVP-HSVtk or controls. GCV (80 mg/kg per day,
intraperitoneal) was started 2 days later in cohorts of size-matched
tumor-bearing mice.
Molecular-Genetic Imaging in Tumor-Bearing Mice
For noninvasive molecular imaging, we used a model of prostate can-
cer based on the human cell line DU145 in which male nudemice bear-
ing tumor xenografts in the subcutaneous area of the right shoulder
were used. To image Luc gene expression, tumor-bearing mice re-
ceived a single dose (150 mg/kg, intraperitoneal) of the substrate
D-luciferin (Xenogen). Photonic emission was imaged with the
In Vivo Imaging System 200 (IVIS200; Xenogen) after tail-vein adminis-
tration of targeted RGD-4C AAVP carrying the Luc gene or controls
(nontargeted AAVP-Luc or scrambled RGD-4C AAVP-Luc). Imaging
parameters were image acquisition time, 1 min; binning, 2; no filter;
f/stop, 1; field of view, 10 cm. Regions of interest (roi) were defined
manually over the tumors for measuring signal intensities, expressed
as photons/sec/cm2/sr.
While BLI can assess transgene-expressing cell viability in experi-
mental systems, it is not clinically applicable. Thus, to assess the via-
bility of the established tumor xenografts, mice were imaged with a
microPET scanner (Concorde Microsystems) at 2 hr post intravenous
administration of [18F]FDG 100 mCi/mouse. [18F]FDG was obtained
commercially (PETNet). To image HSVtk gene expression, PET imag-
ing was performed at 1–2 hr after intravenous administration of the ra-
diolabeled nucleoside analog [18F]FEAU. PET imaging was performed
using a microPET R4 (Concorde Microsystems) equipped with a com-
puter-controlled positioning bed. It has a 10.8 cm transaxial and 8 cm
axial field of view (fov) without a septa and operates in a three-dimen-
sional list mode. Fully three-dimensional list mode data were collected
using an energy window of 350–750 kiloelectron volts and a time win-
dow of 6 ns. All raw data were first sorted into three-dimensional sino-
grams, followed by Fourier rebinning and OSEM image reconstruction
using ASIPRO VM software (Concord Microsystems). Image pixel size
was 1 mm transaxially with a 1.2 mm slice thickness.
Radiolabeled [18F]FEAU was synthesized to radiochemical purity
greater than 99% by using 5-ethyluracil-2,5-bis-trimethylsilyl ether
as the pyrimidine base for condensation with 1-bromo-2-deoxy-
2-[18F]fluoro-3,5-di-O-benzoyl-a-D-arabinofuranose (Alauddin et al.,
2003). To quantitate the [18F]FEAU or [18F]FDG-derived radioactivity
concentration in tumors and other organs and tissues, regions of inter-
est were drawn on images and the measured values converted from
nCi/mm3 into % injected dose per gram (%ID/g; Tjuvajev et al., 1998).
Repetitive [18F]FEAU PET imaging was performed at days 0, 3, 5, 10,
and 16 post administration of targeted AAVP carrying the HSVtk
gene or control nontargeted AAVP; GCV treatment was administered
between days 11 and 19. Of note, PET imaging at day 16 was per-
formed at 24 hr after GCV dosing to allow for sufficient elimination of
GCV, which would otherwise compete with FEAU for phosphorylation
by the HSVtk enzyme. PET imaging with [18F]FDGwas repeated at day
17 after AAVP administration to assess the viability of residual tumor, if
any.
Immunohistochemistry
Anesthetized mice were killed and perfused with PBS containing 4%
PFA. Tumor vascularization was assessed on frozen sections by using
a rat anti-mouse CD31 antibody (BD Biosciences). Apoptosis analysis
was performed on paraffin-embedded sections with a TUNEL kit
(Promega). For phage immunodetection, paraffin sections were incu-
bated with a rabbit anti-phage antibody (Sigma) followed by a peroxi-
dase-conjugated anti-rabbit secondary antibody (Dako). For GFP im-
munostaining, tissues were fixed for 2 hr in PBS containing 2% PFA
and equilibrated for 48 hr in PBS containing 15% sucrose. Cryosec-
tions were postfixed in PBS containing 4%PFA for 20min and blocked
with 5% goat serum in PBS containing 1% BSA and 0.1% Triton X-
100. Tissue sections were incubated with a rabbit affinity-purified
GFP antibody (Molecular Probes) in 2%goat serum and 1%BSA. Sec-
tions were then stained with the secondary antibody AlexaFluor 488-
conjugated goat anti-rabbit (Molecular Probes). av integrin immuno-
stainings were performed on acetone-fixed frozen sections of tumors
removed from PBS-perfused animals. Sections were incubated for
1 hr with a rat anti-integrin av monoclonal antibody (Chemicon), fol-
lowed by a secondary Cy3-conjugated goat anti-rat antibody (Jackson
ImmunoResearch).
Supplemental Data
Supplemental Data include five figures and two tables and can be
found with this article online at http://www.cell.com/cgi/content/full/
125/2/385/DC1/.
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